Cargando…

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study

BACKGROUND: The ALSYMPCA trial revealed radium‐223 (Ra‐223) to be a life‐prolonging agent for bone metastatic castration‐resistant prostate cancer (CRPC). However, only 2.8% of enrolled patients in that clinical trial were Asian, and no Japanese patients were enrolled. Several retrospective studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawahara, Takashi, Miyoshi, Yasuhide, Ninomiya, Sahoko, Sato, Motoki, Takeshima, Teppei, Hasumi, Hisashi, Makiyama, Kazuhide, Uemura, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles: Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544379/ https://www.ncbi.nlm.nih.gov/pubmed/35976620 http://dx.doi.org/10.1111/iju.15008

Ejemplares similares

The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer
por: Tatenuma, Tomoyuki, et al.
Publicado: (2019)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings
por: Kawahara, Takashi, et al.
Publicado: (2019)

A retrospective study on the possible systematic inflammatory response markers to predict the prognosis of patients with bladder cancer undergoing radial cystectomy
por: Ninomiya, Sahoko, et al.
Publicado: (2020)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
por: Hashimoto, Kohei, et al.
Publicado: (2020)

Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer
por: Ninomiya, Sahoko, et al.
Publicado: (2019)

Sperm cryopreservation before definitive therapy for early‐stage prostate cancer: A single institution experience
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

Transurethral laser lithotripsy using the Mitrofanoff urethral conduit for bladder stones: a case report
por: Yamamoto, Shotaro, et al.
Publicado: (2023)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
por: Sugimura, Rumiko, et al.
Publicado: (2019)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

A lower psoas muscle index predicts a poorer prognosis in metastatic hormone‐naïve prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2020)

Paraganglioma in the bladder: a case report
por: Iwamoto, Genta, et al.
Publicado: (2017)

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer
por: Makita, Kenji, et al.
Publicado: (2023)

Successful treatment of ureteral stricture after total hysterectomy: An antegrade ureteroscopic approach facilitates the insertion of a guidewire for endoscopic dilation
por: Iwamoto, Genta, et al.
Publicado: (2019)

Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma
por: Ninomiya, Sahoko, et al.
Publicado: (2018)

Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy
por: Uemura, Koichi, et al.
Publicado: (2017)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide
por: Kumano, Yohei, et al.
Publicado: (2019)

Skene duct adenocarcinoma in a patient with an elevated serum prostate-specific antigen level: a case report
por: Tsutsumi, Sohgo, et al.
Publicado: (2018)

Ureter metastatic castration-resistant prostate cancer: a case report
por: Tsutsumi, Sohgo, et al.
Publicado: (2017)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ep0cgcs9v2s103enukucdcf9mc